(Q38114850)

29 August 2017

title

Burden of disease: psoriasis and psoriatic arthritis (English)

1 reference

29 August 2017

author name string

Wolf-Henning Boehncke

series ordinal

1

1 reference

29 August 2017

Alan Menter

series ordinal

2

1 reference

29 August 2017

language of work or name

1 reference

1 October 2013

1 reference

American Journal of Clinical Dermatology

29 August 2017

published in

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

377-388

1 reference

https://scigraph.springernature.com/pub.10.1007/s40257-013-0032-x

29 August 2017

exact match

0 references

cites work

Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Psoriatic arthritis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Psoriatic arthritis--what the dermatologist needs to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Economic burden of comorbidities in patients with psoriasis is substantial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Epidemiology and potential pathomechanisms of cardiovascular comorbidities in psoriasis: a report from the GRAPPA 2010 annual meeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Associated comorbidities in psoriasis and inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

New insights into the concept of psoriatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Psoriatic arthritis: update on pathophysiology, assessment and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Predictors for radiological damage in psoriatic arthritis: results from a single centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Treatment recommendations for psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire and the role of dermatologists: a report from the GRAPPA 2009 annual meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

IL-17 receptor and its functional significance in psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0032-X

10.1007/S40257-013-0032-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1031896048

0 references

1 reference